GRI and SASB Content Indices
 

 

 

 

GRI Indicator
Description
Reference

 

SDG Alignment*

 

 

GRI 102: GENERAL DISCLOSURES 2016

 

Organizational Profile 2019

 

 

 

 

 

102-1

Name of the organization

Biogen Inc.

 

 

102-2

Activities, brands, products, and services

Message from the CEO– 2019 Year in Review

Item 1., Business, 2019 Form 10-K, pages 1-28

 

 

102-3

Location of headquarters

Corporate Headquarters: Cambridge, Massachusetts (U.S.)

 

 

102-4

Location of operations

Pharmaceutical Operations & Technology

Item 2., Properties, 2019 Form 10-K, pages 48-49

 

 

102-5

Ownership and legal form

Board of Directors

Corporate Governance Documents

 

 

102-6

Markets served

Item 1., Business, 2019 Form 10-K, pages 9-11

 

 

102-7

Scale of the organization

Highlights – 2019 Annual Report

Item 1., Business, 2019 Form 10-K, pages 1-28

Item 6., Selected Financial Data, 2019 Form 10-K, pages 52-54

 

 

102-8

Information on employees and other workers

Item 1., Business, 2019 Form 10-K, pages 29-32

 

 

102-9

Supply chain

Item 1., Business, 2019 Form 10-K, pages 27-28 

Goal 12

 

102-10

Significant changes to the organization and its supply chain

Item 1., Business, 2019 Form 10-K, pages 2-3 

 

 

102-11

Precautionary Principle or approach

Biogen applies the precautionary approach by achieving carbon neutrality, ensuring the safety of patients, and performing detailed risk analyses related to its operations.

 

 

102-12

External initiatives

Our Guiding Principles

Advocacy Engagement   

Community and Environment Section – 2019 Year in Review

 

 

102-13

Membership of associations

Community and Environment Section – 2019 Year in Review

Biogen membership associations:

RE100 Company – Global initiative uniting more than 100 influential businesses committed to 100% renewable electricity

Pharmaceutical Supply Chain Initiative (PSCI) – Organization of leading global pharmaceutical companies focused on increasing the capabilities and responsibility of our supply chains

Pharmaceutical Product Stewardship Work Group – Association for drug and sharp manufacturers and marketers formed to address the disposal of unused and unwanted pharmaceutical products.

 

 

 

 

 

102-14

Statement from senior decision-maker

Message from the CEO– 2019 Year in Review

 

   

 

102-15

Key impacts, risks, and opportunities

Item 1A., Business, 2019 Form 10-K, pages 33-35

Two important long-term emerging risks identified are regulatory movement on product pricing and the ability to obtain adequate coverage, pricing and reimbursement from third-party payors. In light of these risks, Biogen has increasingly engaged with Health Technology Assessment (HTA) authorities around the world early in the drug development process. These formal scientific advice programs have yielded great insights into the perceived value of the products in Biogen’s development pipeline and the types of evidence needed to help increase their potential for reimbursement. Additional Biogen conducts assessments to quantify the healthcare value our products provide to the communities for which it operates.    

 

   

 

Ethics and Integrity

 

 

102-16

Values, principles, standards, and norms of behavior

Code of Business Conduct (Values in Action)

Our Guiding Principles

 

   

 

102-17

Description of internal and external mechanisms for: seeking advice

Code of Business Conduct (Values in Action)

 

 

 

 

102-18

Governance structure

Executive Leadership

Board of Directors

Corporate Governance Documents

 

   

 

102-30

Highest governance body’s role

Code of Business Conduct (Values in Action)

Sustainability Policy

Environmental Health and Safety Policy

 

 

 

 

102-33

Process for communicating critical concerns to the highest governance body.

Code of Business Conduct (Values in Action)

 

 

 

 

Stakeholder Engagement

 

 

102-40

List of stakeholder groups

GRI Materiality Assessment

 

 

   

 

102-41

Collective bargaining agreements

Approximately 2.2 percent of Biogen’s employees are under a collective bargaining agreement using a time-weighted average basis. All of these employees worked in the Hillerød, Denmark, manufacturing facility. In August 2019 Biogen completed the sale of all of the outstanding shares of its subsidiary that owned its biologics manufacturing operations in Hillerød, Denmark to FUJIFILM Corporation. 2019 total turnover data does not include the 800 employees who continued employment under Fujifilm ownership.

 

   

 

102-42

Identifying and selecting stakeholders

GRI Materiality Assessment

 

   

 

102-43

Approach to stakeholder engagement

GRI Materiality Assessment

 

   

 

102-44

Key topics and concerns raised

GRI Materiality Assessment

 

   

 

Reporting Practice

 

 

102-45

Entities included in the consolidated financial statements

All major entities are included in the boundaries of this report. See the 2019 Form 10-K

 

   

 

102-46

Defining report content and topic Boundaries

GRI Materiality Assessment

Reporting Section  – 2019 Year in Review

 

   

 

102-47

List of material topics

GRI Materiality Assessment

 

   

 

102-48

Restatements of information

No restatements were made

 

   

 

102-49

Changes in reporting

No significant changes from the previous reporting period  

 

   

 

102-50

Reporting period

Data covers fiscal year 2019; ending December 31, 2019. Some activities from 2020 are also included

 

   

 

102-51

Date of most recent report

April 20, 2020

 

   

 

102-52

Reporting cycle

We report on an annual basis

 

   

 

102-53

Contact point for questions regarding the report

Corporate Social Responsibility contact:

public.affairs@biogen.com

 

   

 

102-54

Claims of reporting in accordance with the GRI Standards

This report has been prepared in accordance with the GRI Standards: Core option

 

   

 

102-55

GRI content index

GRI Content Index

 

   

 

102-56

External assurance

ERM CVS Independent Assurance Statement to Biogen Inc.

 

   

 

GRI 103: TOPICS AND TOPIC BOUNDARIES

   
103-1

Explanation of the material topic and its Boundary

GRI Materiality Assessment

Reporting Section  – 2019 Year in Review

 

   

 

103-2

The management approach and its components

Purpose and Performance Section 2019 Year in Review

 

   

 

103-3

Evaluation of the management approach

Consolidated Financial Statements, 2019 Form 10-K, pages F-80-82 

2019 Annual Report

 

   

 

GRI 200-400: TOPIC-SPECIFIC DISCLOSURES 2016

   

Economic

 

 

   

Economic Performance

 

 

   
201-1

Direct economic value generated and distributed

GAAP to Non-GAAP Reconciliation Section 2019 Annual Report

Item 6., Selected Financial Data, 2019 Form 10-K, page 51, F-75

 

   

 

201-2

Financial implications and other risks and opportunities due to climate change

Biogen acknowledges the desires of its investors to better understand Biogen’s climate-related financial risks. Biogen is taking steps to align with the four recommendations outlined by the Task Force on Climate-related Financial Disclosures (TCFD). Disclosure of Biogen’s progress as well as climate-related financial risks and opportunities can be found in its 2019 CDP Climate Change disclosure. In alignment with the TCFD, Biogen will look to incorporate material risks and opportunities into our reporting in future years.

 

   

 

201-3

Defined benefit plan obligations and other retirement plans

Consolidated Financial Statements, 2019 Form 10-K, page F-75

 

   

 

Indirect Economic Impacts

 

 

   
203-2

Significant indirect economic impacts

2019 Year in Review  

GRI Materiality Assessment

Goal 3

Goal 4

   

 

Procurement Practices

 

 

   
204-1

Proportion of spending on local suppliers

Not applicable

Biogen discloses this information only on a global level

Our Guiding Principles

Supplier Diversity – Working With Us

Goal 5

Goal 8

   

 

Environment

 

 

   

Water and Effluents

 

 

   
303-1

Interactions with water as a shared resource

Community and Environment Section – 2019 Year in Review

Data Table – 2019 Year in Review

2020 CDP Water Security disclosure

Goal 6

   

 

303-3

Water withdrawal

Community and Environment Section – 2019 Year in Review

Data Table – 2019 Year in Review

2020 CDP Water Security disclosure

Goal 6

   

 

303-4

Water discharge

Community and Environment Section – 2019 Year in Review

Data Table – 2019 Year in Review

2020 CDP Water Security disclosure

Goal 6

   

 

303-5

Water consumption

Community and Environment Section – 2019 Year in Review

Data Table – 2019 Year in Review

2020 CDP Water Security disclosure

Goal 6

   

 

Emissions

 

 

   
305-1

Direct (Scope 1) GHG emissions

Community and Environment Section – 2019 Year in Review

Data Table – 2019 Year in Review

Biogen 2020 CDP Climate Change disclosure

Goal 7

 

Goal 13

   

 

305-2

Energy indirect (Scope 2) GHG emissions

Community and Environment Section – 2019 Year in Review

Data Table – 2019 Year in Review

Biogen 2020 CDP Climate Change disclosure

Goal 7

 

Goal 13

   

 

305-3

Other indirect (Scope 3) GHG emissions

Community and Environment Section – 2019 Year in Review

Data Table – 2019 Year in Review

Biogen 2020 CDP Climate Change disclosure

Goal 7

 

Goal 13

   

 

305-5

Reduction of GHG emissions

Community and Environment Section – 2019 Year in Review

Data Table – 2019 Year in Review

Biogen 2020 CDP Climate Change disclosure

Goal 7

 

Goal 13

   

 

Effluents and Waste

 

 

   
306-2

Waste by type and disposal method

Community and Environment Section – 2019 Year in Review

Data Table – 2019 Year in Review

Goal 12

   

 

Environmental Compliance

 

 

   
307-1

Non-compliance with environmental laws and regulations

There were no significant instances of non-compliance in 2019

Our Guiding Principles

Item 1A., Risk Factors, 2019 Form 10-K, page 47

Goal 12

   

 

Supplier Environmental Assessments

 

 

   
308-1

New suppliers that were screened using environmental criteria

Community and Environment Section – 2019 Year in Review

Reporting Section  – 2019 Year in Review

Goal 12

   

 

308-2

Negative environmental impacts in the supply chain and actions taken

Community and Environment Section – 2019 Year in Review

Reporting Section  – 2019 Year in Review

Item 1A., Risk Factors, 2019 Form 10-K, page 47

Goal 12

   

 

Social

 

 

   

Social

 

 

   
401-1

New employee hires and employee turnover

Data Table – 2019 Year in Review

Break down by age group, gender is not shared publicly.

 

   

 

 

 

Occupational Health and Safety

   
403-1

Occupational health and safety management system

Our People Section – 2019 Year in Review

Environmental, Health and Safety Policy Statement

Goal 3

 

Goal 8

   

 

403-2

Hazard identification, risk assessment, and incident investigation

Our People Section – 2019 Year in Review

Environmental, Health and Safety Policy Statement

Goal 3

 

Goal 8

   

 

403-4

Worker participation, consultation, and communication on occupational health and safety

Our People Section – 2019 Year in Review

Environmental, Health and Safety Policy Statement

Goal 3

 

Goal 8

   

 

403-9

Work-related injuries

Our People Section – 2019 Year in Review

Data Table – 2019 Year in Review

Environmental, Health and Safety Policy Statement

Goal 3

 

Goal 8

   

 

Diversity and Equal Opportunity

 

 

   
405-1

Diversity of governance bodies and employees

Our People Section – 2019 Year in Review

Data Table – 2019 Year in Review

Board of Directors

Goal 5

   

 

405-2

Ratio of basic salary and remuneration of women to men

Confidentiality constraints

Biogen does not disclose externally any salary and wages related data except the Executive Compensation of the Executive Committee and Board of Directors

 

   

 

Local Communities

 

 

   
413-1

Operations with local community engagement, impact assessments, and development programs

Our People Section – 2019 Year in Review

Community and Environment Section – 2019 Year in Review  

Grants Management and Strategic Giving

Biogen also supports local communities through grants provided through the Biogen Foundation. Recipients of grants equal to or greater than $100,000 in 2019 include:

·       Dana-Farber Cancer Institute
East End House

·       Friends of North Carolina Museum of Natural Sciences

·       North Carolina State University Foundation  

·       University of North Carolina at Chapel Hill

Goal 3

 

Goal 4

 

   

 

Supplier Social Assessment

 

 

   
414-1

New suppliers that were screened using social criteria

Our People Section – 2019 Year in Review

Reporting Section  – 2019 Year in Review

Supplier Diversity – Working With Us

Code of Business Conduct (Values in Action)

Goal 5

 

Goal 8

Goal 12

   

 

414-2

Negative social impacts in the supply chain and actions taken

Supplier Diversity – Working With Us

Code of Business Conduct (Values in Action)

Reporting Section  – 2019 Year in Review

Goal 5

 

Goal 8

Goal 12

   

 

Public Policy

 

 

   
415-1

Political contributions

Our Guiding Principles

Political Contributions Policy

Political Contributions Disclosure

2019 Form 10-K

Goal 16

   

 

Customer Health and Safety

 

 

   
416-1

Assessment of the health and safety impacts of product and service categories

Patients Section – 2019 Year in Review

Pioneering Science Section – 2019 Year in Review

2019 Annual Report

Our Guiding Principles

Patient Safety

Product Stewardship

 Goal 3

   

 

416-2

Incidents of non-compliance concerning the health and safety impacts of products and services

There were no significant instances of non-compliance in 2019

Pioneering Science Section – 2019 Year in Review

2019 Annual Report

Patient Safety

Product Stewardship

 Goal 3

   

 

Marketing and Labeling

 

 

   
417-1

Requirements for product and service information and labeling

Our Guiding Principles

Patient Safety

Product Stewardship

 Goal 3

   

 

417-2

Incidents of non-compliance concerning product and service information and labeling

There were no significant instances of non-compliance in 2019

Our Guiding Principles

 Goal 3

   

 

417-3

Incidents of non-compliance concerning marketing communications

There were no significant instances of non-compliance in 2019


Our Guiding Principles

 Goal 3

   

 

Customer Privacy

 

 

   
418-1

Substantiated complaints concerning breaches of customer privacy and losses of customer data

There were no significant instances of breaches of customer privacy or losses of customer data in 2019 

Our Guiding Principles

Global Privacy Program

     

 

*Assessed using the SDG Compass: Linking the SDGs and GRI Standards available on the GRI website’s resource library.

 

 

Biogen 2019 Sustainability Accounting Standard Board (SASB) Disclosure

Biogen is committed to providing meaningful sustainability information to stakeholders. We disclose information about our sustainability and governance, social and environmental practices via our Annual Report, Proxy Statements, CDP disclosures and Biogen’s website, found at www.biogen.com.


We continue to enhance our sustainability reporting and in 2019 we published our first integrated report and began disclosure aligned with the SASB Biotechnology & Pharmaceuticals industry standard, version 2018-10, which can be found online here. This is an initial step in our evolution towards greater integration of sustainability disclosure in our financial reporting.


As we are currently in the process of developing robust sustainability disclosure processes, some metrics are not available for disclosure this year. We look forward to providing additional reporting in subsequent disclosures.


All data in this SASB disclosure is as of, or for the year-ended December 31, 2019 unless otherwise noted.

 

 

Code

Accounting Metric

Disclosure

Safety of Clinical Trial Participants

HC-BP-210a.1
Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials
Biogen has a Global Pharmacovigilance (PV) team comprised of medical and scientific professionals with extensive safety and/or clinical or healthcare experience who are trained in PV and worldwide health authority regulations relevant to medicinal product safety.
Biogen’s safety signal management processes, combined with our robust safety governance framework, allow Biogen to determine if new safety information on our products (a ‘signal’) poses a risk to patients and how best to manage, mitigate and communicate the risk.  All safety and benefit/risk decisions for marketed and investigational products are made at the Safety Monitoring Committee (SMC). The Safety team collaborates with Regulatory Affairs to communicate product information in a timely, transparent, and accurate manner to regulatory agencies across the globe.
In addition to complying with our company’s global standards, the conduct of our clinical trials adheres to the International Council for Harmonisation Good Clinical Practice (ICH GCP) standards and to the principles that have their origin in the Declaration of Helsinki.
 
Each country has its own regulatory authority with its own regulations, or laws, for conducting a clinical trial. The regulatory authority reviews and approves the protocol and ensures that the clinical trial follows national regulations.
An Institutional Review Board (IRB)or Ethics Committee (EC) is an independent committee that includes medical, scientific, and non-scientific members, whose responsibility is to protect the rights, welfare, safety, and well-being of clinical trial participants. Each clinical trial location is monitored by a specific IRB / EC. It is responsible for reviewing all clinical trials, as well as conducting ongoing reviews of active clinical trials.
For more information please visit our clinical trials webpage  

 

HC-BP-210a.2
Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)
Biogen is committed to transparent ESG reporting and intends expand its SASB disclosure in the following year.

HC-BP-210a.3
Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries
Biogen did not sustain any monetary losses in the reporting period as a result of legal proceedings associated with the conduct as described.
Biogen discloses all material legal and regulatory proceedings in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Access to Medicines

HC-BP-240a.1
Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index
See our 2019 Year in Review Patients Section for description of our expanded access program and spinal muscular atrophy (SMA)-focused individual patient humanitarian access program, which enable access to SPINRAZA in priority countries.
HC-BP-240a.2
List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)
Biogen has no products on the WHO List of Prequalified Medicinal Products.

Affordability & Pricing

HC-BP-240b.1
Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period
Biogen does not comment on confidential legal matters
HC-BP-240b.2
Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year
We regularly review our pricing strategy and prioritize patient access to our therapies. We have a value-based contracting program designed to align the price of our therapies to the value our therapies deliver to patients. We also work with regulators, clinical researchers, ethicists, physicians and patient advocacy organizations and communities, among others, to determine how best to address requests for access to our investigational therapies in a manner that is consistent with our patient-focused values and compliant with regulatory standards and protocols. Additional information is available here:
•      2019 10-k
•      Biogen Pricing Principles

HC-BP-240b.3
Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year
We regularly review our pricing strategy and prioritize patient access to our therapies. We have a value-based contracting program designed to align the price of our therapies to the value our therapies deliver to patients. We also work with regulators, clinical researchers, ethicists, physicians and patient advocacy organizations and communities, among others, to determine how best to address requests for access to our investigational therapies in a manner that is consistent with our patient-focused values and compliant with regulatory standards and protocols. Additional information is available here:
•      2019 10-k
•      Biogen Pricing Principles

Drug Safety

HC-BP-250a.1
List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database
There were no listings relevant to Biogen’s products on the FDA’s MedWatch Safety Alerts for Human Medical Products database in 2019.
Tecfidera (dimethyl fumarate) was listed on the April – June 2019 Potential Signals of Serious Risks/New Safety Information Identified report from the FDA Adverse Event Reporting System (FAERS).
HC-BP-250a.2
Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System
Biogen is committed to transparent ESG reporting and intends expand its SASB disclosure in the following year.
HC-BP-250a.3
Number of recalls issued; total units recalled
Biogen did not issue any drug product recalls in 2019.
HC-BP-250a.4
Total amount of product accepted for takeback, reuse, or disposal
Due to the low volume of its products, at this time, Biogen does not manage a formal product takeback, reuse or disposal program. Per regulatory requirements, Biogen participates in several product takeback programs across various U.S. states or counties, and several other countries. In addition, Biogen provides guidance on disposal methods of its products.
HC-BP-250a.5
Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practalsoices (cGMP), by type
The FDA issued Biogen 11 Form 483 observations in 2019. Biogen did not receive any FDA enforcement actions associated with warning letters, seizures, recalls or consent decrees in 2019.
 
  • Our former Hillerød facility received six (6) observations.
  • Our RTP Drug Substance facility received five (5) observations.
 
Corrective actions were nearly all procedural update driven that also optimized the processes, however, did not implicate the processes as being ineffective.

 

Counterfeit Drugs

HC-BP-260a.1
Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting
Counterfeit medicines – a multi-billion dollar annual illegal industry, estimated by the World Customs Organization – put patients at risk and pose an ever growing concern for the biopharmaceutical industry. Biogen takes the issue of counterfeit, adulterated and compromised drugs very seriously.
As part of Biogen’s comprehensive supply chain security strategy, we aim to disrupt diversions, counterfeiting, theft and other nefarious activities through the following:
  • Implementing sophisticated technology into our product packaging
  • Auditing current supply chain partners to ensure industry best practice requirements are met regarding product security
  • Monitoring program across value stream to identify potential threats to supply chain resiliency and robustness
In addition, Biogen has a Global Serialization Program to meet the increasing global regulatory requirements for managing supply chain operations in a secure and traceable way. These regulations are built on the concepts of serialization and “track and trace.” Serialization is the use of globally unique codes that are printed on individual medicine packs and communicated to supply chain partners for the purpose of authentication, and in some cases, improved product management, such as preventing dispensation of expired product or managing processes for returns and recalls. We are also investing in packaging operations, distribution sites and information technology infrastructure across the supply chain to support serialization and assure compliance to serialization requirements in an increasing number of markets, including the U.S. and the European Union (EU).
HC-BP-260a.2
Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products
The Global Serialization Program allows EU pharmacists to check a medication against a unique list of numbers to be certain that the products they are dispensing were manufactured by Biogen and not swapped out by someone else between the time they left the manufacturing facility and arrived at a pharmacy or hospital. The serial numbers are highly randomized, rendering them extremely difficult for counterfeiters to imitate.
HC-BP-260a.3
Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products
Biogen did not take any actions in the reporting period that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products.

Ethical Marketing

HC-BP-270a.1
Total amount of monetary losses as a result of legal proceedings associated with false marketing claims
Biogen did not sustain any monetary losses in the reporting period as a result of legal proceedings associated with the conduct as described.
Biogen discloses all material legal and regulatory proceedings in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
HC-BP-270a.2
Description of code of ethics governing promotion of off-label use of products
Please visit here for a description of Biogen’s approach to off-label use.

Employee Recruitment, Developing & Retention

HC-BP-330a.1
Discussion of talent recruitment and retention efforts for scientists and research and development personnel
See our 2019 Year in Review Our People Section for further information on our recruitment, retention and development efforts.
HC-BP-330a.2
(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others
See our 2019 Year in Review GRI Data Table for total voluntary and involuntary turnover rates.

Supply Chain Management

HC-BP-430a.1
Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients
See our 2019 Year in Review 2019 Reporting Section

 

Business Ethics

HC-BP-510a.1
Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery
Biogen did not sustain any monetary losses in the reporting period as a result of legal proceedings associated with the conduct as described.
Biogen discloses all material legal and regulatory proceedings in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
HC-BP-510a.2
Description of code of ethics governing interactions with health care professionals
We comply with the Pharmaceutical Research and Manufacturers of America’s (PhRMA) Code on Interactions with Healthcare Professionals.
See our Code of Business Conduct section on Interactions with Healthcare Professionals.

Activity Metrics

HC-BP-000.A
Number of patients treated
In 2019 we remained a global market leader in MS with an approximately 34% market share of the approximately one million MS patients being treated worldwide.  Additional information is available in our 2019 Annual Report
HC-BP-000.B
Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)
The number of drugs actively on the market is ten. We closed 2019 with a pipeline that included 27 clinical programs:
•     Number in Phase 1 = 9
•     Number in Phase 2 = 12
•     Number in Phase 3 = 6
 
More information on our product portfolio and line is provided on our website.
Values are as of December 31, 2019.

 

 

The inclusion of information contained in this disclosure should not be construed as a characterization regarding the materiality or financial impact of that information. Please also see our 2019 Annual Report on Form 10-K filed on February 6, 2020, and other publicly filed documents available at https://biogen.gcs-web.com/investor-relations.


This report contains information about Biogen and may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements, other than statements of historical facts, may be forward -looking statements. Biogen cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and Biogen assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance. Factors that can cause results to differ, as well as additional factors that can affect forward-looking statements, are discussed in Biogen’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, accessible on the SEC’s website at www.sec.gov and on Biogen’s website at www.biogen.com.